Zobrazeno 1 - 5
of 5
pro vyhledávání: '"B.L. Shashi Bhushan"'
Autor:
Anuja Pandit, Nirav Bhalani, B.L. Shashi Bhushan, Parshottam Koradia, Shweta Gargiya, Vinay Bhomia, Kevinkumar Kansagra
Publikováno v:
International Journal of Infectious Diseases, Vol 105, Iss , Pp 516-521 (2021)
Objective: To evaluate the efficacy and safety of pegylated interferon alfa-2b (PEG IFN-α2b) along with the standard of care (SOC) in subjects with moderate COVID-19. Methods: In this phase 2, randomized, open-label study, adult subjects aged ≥18
Externí odkaz:
https://doaj.org/article/db1045fd9fbc4939a9d4129a5d9bf40c
Autor:
Anuja Pandit, Nirav Bhalani, B.L. Shashi Bhushan, Parshottam Koradia, Shweta Gargiya, Vinay Bhomia, Kevinkumar Kansagra
Publikováno v:
International Journal of Infectious Diseases, Vol 109, Iss , Pp 322- (2021)
Externí odkaz:
https://doaj.org/article/a241828a658d44b9a2af2cd2625831a8
Autor:
Nirav Bhalani, Anuja Pandit, Parshottam Koradia, Vinay Bhomia, Kevinkumar Kansagra, B.L. Shashi Bhushan, Shweta Gargiya
Publikováno v:
International Journal of Infectious Diseases
International Journal of Infectious Diseases, Vol 105, Iss, Pp 516-521 (2021)
International Journal of Infectious Diseases, Vol 105, Iss, Pp 516-521 (2021)
Objective: To evaluate the efficacy and safety of pegylated interferon alfa-2b (PEG IFN-α2b) along with the standard of care (SOC) in subjects with moderate COVID-19. Methods: In this phase 2, randomized, open-label study, adult subjects aged ≥18
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::144cfe4c1e33e7c1ecdf3099cf686acb
http://europepmc.org/articles/PMC7944859
http://europepmc.org/articles/PMC7944859
Autor:
Nirav Bhalani, Kevinkumar Kansagra, Anuja Pandit, Parshottam Koradia, Vinay Bhomia, Shweta Gargiya, B.L. Shashi Bhushan
Publikováno v:
International Journal of Infectious Diseases
International Journal of Infectious Diseases, Vol 109, Iss, Pp 322-(2021)
International Journal of Infectious Diseases, Vol 109, Iss, Pp 322-(2021)
To evaluate the efficacy and safety of pegylated interferon alfa-2b (PEG IFN-α2b) along with the standard of care (SOC) in subjects with moderate COVID-19.In this phase 2, randomized, open-label study, adult subjects aged ≥18 years with RT-PCR con
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e9473d49c8d61f01d2a96b28b0b93047
https://doi.org/10.1016/j.ijid.2021.06.030
https://doi.org/10.1016/j.ijid.2021.06.030
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.